ARTICLE | Company News
Theravance sells Vibativ to Cumberland
November 16, 2018 4:01 PM UTC
Theravance Biopharma Inc. (NASDAQ:TBPH) sold antibiotic Vibativ telavancin to Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) for $25 million. Theravance is eligible for tiered royalties of up to 20%.
Theravance recorded $5.4 million in Vibativ sales in 2Q18. The drug is an injectable lipoglycopeptide antibiotic...